KERX Financial Facts

Other research and development: 6.24M
Basic and diluted net loss per common share: -0.03
See Full Income Statement

Property, plant and equipment, net: 91K
Additional paid-in capital: 478.81M
See Full Balance Sheet

Earnings History for Keryx Biopharmaceuticals Inc. (KERX)

  |   Expand Research on KERX
Next EPS Date 8/6/13 *Est. EPS Growth Rate +76.9% *Last Qtr.
Average EPS % Beat Rate -37.3% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +5.4%    
Date  Qtr EPS Cons. Surprise Revs Cons. Estimize EPS/Revs Gd. % Since Details
5/7/13 Q113 -$0.03-$0.01 -$0.02$7M$5.83M N/A / N/A N/A +0.5% Details
3/11/13 Q412 -$0.09-$0.08 -$0.01N/AN/A N/A / N/A N/A +9.3% Details
3/8/11 Q410 -$0.09-$0.06 -$0.03N/A$2.82M N/A / N/A N/A +101.8% Details
8/8/11 Q211 -$0.05-$0.03 -$0.02$5M$5M N/A / N/A N/A +130.7% Details
2/29/12 Q411 -$0.12-$0.14 +$0.02N/AN/A N/A / N/A N/A +141.9% Details
11/2/11 Q311 -$0.15-$0.12 -$0.03N/AN/A N/A / N/A N/A +162.4% Details
11/8/12 Q312 -$0.08-$0.07 -$0.01N/AN/A N/A / N/A N/A +238.8% Details
8/7/12 Q212 -$0.02-$0.09 +$0.07N/AN/A N/A / N/A N/A +334.1% Details
Like KERX Earnings? Also take a look at BLK, AEZS, SNY, IPXL

KERX Earnings News